Library
of Slides and Posters
Clinical course
of increased LFTs and hepatic events associated with ritonavir (RTV)-boosted tipranavir
(TPV/r) based therapy in the RESIST trials
M Sulkowski1 and others.
Abstract Number H-1899.
Tipranavir/r
demonstrates superior and durable treatment response compared with comparator
PI/r in highly treatment experienced patients: Week 96 RESIST 1 and 2 results
C
Farthing and others.,Abstract Number H-1385.
Impact
of protease mutations L33 F/I, V82A, I84V, and L90M on ritonavir-boosted protease
inhibitor susceptibility
P
Piliero and others. Abstract Number H-998.
Safety,
Tolerability & Efficacy of Abacavir/Lamivudine/Zidovudine vs. Atazanavir & Lamivudine/Zidovudine
in Antiretroviral Naïve Subjects
(PowerPoint Slides)
P
Kumar and others. ESS100327: ACTION Study No. H-1058. Copyright
GlaxoSmithKline. Used with permission 2006.
When
Does the CD4+ Cell Count Plateau? Evidence from Subjects Treated with a Lopinavir/ritonavir-based
Regimen for Up to 7 Years
M
King and others. Abstract H-1401.
Lower
Adherence to HAART Observed Prior to Transient HIV-1 Viremia (“Blip”)
T
Podsadecki and others. Poster #H-992
Comparative
Assessment of Changes in Blood Pressure (BP) Through 48-weeks from a Phase 3 Clinical
Trial of Lopinavir/ritonavir (LPV/r)
B
da Silva and others. Poster #75.
Short-Term
Safety and Tolerability of ABC/3TC Administered Once-daily (QD) Compared with
the Separate Components Administered Twice-daily (BID): Results from ESS101822
(ALOHA)
M
Kubota and others. Poster Number H-1904. CopyrightGlaxoSmithKline.
Used with permission, 2006.
Lower
Reported Rate of Suspected Hypersensitivity Reactions (HSR) to Abacavir (ABC)
Among Black Patients
C Brothers and others. CopyrightGlaxoSmithKline. Used
with permission, 2006.
The
ALERT Study: A Planned Week 24 Interim Analysis of Once Daily Boosted Fosamprenavir
or Atazanavir with Tenofovir/Emtricitabine
K Smith and others. CopyrightGlaxoSmithKline.
Used with permission, 2006.
The
KLEAN Study: FPV/r BID vs LPV/r BID + ABC/3TC QD in ART Naïve Subjects
48
Week analysis demonstrates rare resistance and non-inferiority
P Yeni and
others. CopyrightGlaxoSmithKline. Used with permission, 2006.
|
|
